The western front of the United States Capitol in Washington, DC.

The American College of Cardiology’s 66th Annual Scientific Session & Expo took place March 17-19, 2017, in Washington, DC.

Genetically guided warfarin dosing can lower AE risk

Print Friendly, PDF & Email


Warfarin tablets
Photo courtesy of
Intermountain Medical Center
Using genetic testing to guide warfarin dosing can lower the risk of combined adverse events (AEs) after elective orthopedic surgery, results of the GIFT trial suggest. In this trial, investigators found that genotype-guided warfarin dosing was associated with a lower risk... [Read Article]
Print Friendly, PDF & Email

Study supports use of rivaroxaban to prevent VTE recurrence

Print Friendly, PDF & Email


Rivaroxaban (Xarelto)
Results of the EINSTEIN CHOICE study suggest rivaroxaban is more effective than, and just as safe as, aspirin for long-term anticoagulation in patients with venous thromboembolism (VTE). In this phase 3 study, patients who had completed 6 to 12 months of anticoagulant therapy were randomized to receive rivaroxaban or aspirin.... [Read Article]
Print Friendly, PDF & Email

Apixaban bests warfarin in real-world analysis

Print Friendly, PDF & Email


Warfarin tablets
An analysis of real-world data suggests elderly patients with non-valvular atrial fibrillation (NVAF) have a lower risk of stroke or systemic embolism and a lower risk of major bleeding if they receive apixaban rather than warfarin. The study also indicates that elderly NVAF patients who receive dabigatran have a similar... [Read Article]
Print Friendly, PDF & Email

Major bleeding lower with dabigatran than warfarin

Print Friendly, PDF & Email


Dabigatran (Pradaxa)
Photo from Boehringer
Ingelheim Pharmaceuticals
Results from the RE-CIRCUIT trial suggest that uninterrupted dabigatran poses a lower risk of major bleeding than uninterrupted warfarin in patients with non-valvular atrial fibrillation (NVAF) who are undergoing catheter ablation. Patients who received dabigatran also had fewer serious and severe adverse events (AEs). ... [Read Article]
Print Friendly, PDF & Email

Drugs demonstrate similar safety profile in ACS trial

Print Friendly, PDF & Email


Aspirin tablets
Photo by Sage Ross
Results of a phase 2 trial suggest rivaroxaban and aspirin have similar safety profiles in patients with acute coronary syndrome (ACS) who are also taking a P2Y12 inhibitor. Researchers found that, overall, the risk of bleeding was similar whether patients received aspirin or rivaroxaban. ... [Read Article]
Print Friendly, PDF & Email

PE patients rarely receive CDT or ST, study shows

Print Friendly, PDF & Email


CT scan showing PE
Image from Medical
College of Georgia
New research suggests US patients with pulmonary embolism (PE) rarely receive catheter-directed thrombolysis (CDT) or systemic thrombolysis (ST). Investigators analyzed data from more than 100,000 patients who were hospitalized for PE and found that roughly 2% received CDT or ST. ... [Read Article]
Print Friendly, PDF & Email